Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.

JCO Precis Oncol · 2022 · PMC9489196 · PMID 36108259

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, as concluded in the 6-year interim analysis of APHINITY, longer follow-up may be needed to assess OS, which did not reach statistical significance in either study. 21 Together, these data suggest that the population of patients who benefit most from dual HER2-targeted therapy has genomically defined HER2-Type breast cancer.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.